Live Breaking News & Updates on புற்றுநோயியல் மெய்நிகர் காங்கிரஸ்

Stay updated with breaking news from புற்றுநோயியல் மெய்நிகர் காங்கிரஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |Faron Pharma. Oy Announcements | Faron Pharma. Oy: Presents at ESMO Immuno-Oncology Virtual Congress

Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as believe , could , should , expect , hope , seek , envisage , estimate , intend , may , plan , potentially , will or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors current expectations and assumptions regarding the Company s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors current beliefs and assumptions and are based on information currently available ....

Julie Seidel , Mark Rogers , David Daley , Markku Jalkanen , Petri Bono , Sandy Jamieson , Lindsey Neville , Jo Turner , Juha Karttunen , Mary Jane Elliott , Maija Hollm , Rupert Dearden , European Society Of Medical Oncology , Turku University , Faron Pharmaceuticals Oy , Panmure Gordon United Kingdom , Oncology Virtual Congress , Company Ph , Cairn Financial Advisers , Consilium Strategic Communications , Faron Pharmaceuticals Ltd , Faron Pharmaceuticals , First North , European Society , Medical Oncology , Immuno Oncology Virtual Congress ,

Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020

F. Hoffmann-La Roche Ltd
Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020
Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020
People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant (after surgery) Tecentriq monotherapy, compared with those without ctDNA
The goal of current treatment in people with MIUC is to provide early intervention to reduce the risk of the disease recurring or spreading to other parts of the body ....

United States , Nathalie Meetz , Levi Garraway , Daniel Grotzky , Patrick Barth , Karsten Kleine , American Society Of Clinical Oncology , Urology Care Foundation , Oncology Esmo Io Virtual Congress , National Collaborating Centre For Cancer , Head Of Global Product Development , Oncology Virtual Congress , National Institute For Health , European Society For Medical Oncology Immuno , Esmo Io Virtual Congress , Roche Group , Virtual Congress , Pharmaceuticals Industry , Roche Group Media Relations , European Society , Medical Oncology Immuno , Chief Medical Officer , Global Product , American Society , Clinical Oncology , World Health Organization Model Lists ,

Presents at ESMO Immuno-Oncology Virtual Congress, 10 Dec 2020 01:00

Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as believe , could , should , expect , hope , seek , envisage , estimate , intend , may , plan , potentially , will or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors current expectations and assumptions regarding the Company s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors current beliefs and assumptions and are based on information currently available to the Dire ....

Julie Seidel , Mark Rogers , David Daley , Markku Jalkanen , Petri Bono , Sandy Jamieson , Lindsey Neville , Jo Turner , Juha Karttunen , Mary Jane Elliott , Maija Hollm , Rupert Dearden , European Society Of Medical Oncology , Turku University , Faron Pharmaceuticals Oy , Panmure Gordon United Kingdom , Oncology Virtual Congress , Company Ph , Cairn Financial Advisers , Consilium Strategic Communications , Faron Pharmaceuticals Ltd , Faron Pharmaceuticals , First North , European Society , Medical Oncology , Immuno Oncology Virtual Congress ,